The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 12, 2013
Filed:
Jan. 17, 2012
Po-ying Chan-hui, Bellevue, WA (US);
Rajiv Dua, Manteca, CA (US);
Ali Mukherjee, Millbrae, CA (US);
Sailaja Pidaparthi, Cupertino, CA (US);
Hossein Salimi-moosavi, Newbury Park, CA (US);
Yining Shi, Freemont, CA (US);
Sharat Singh, Rancho Santa Fe, CA (US);
Po-Ying Chan-Hui, Bellevue, WA (US);
Rajiv Dua, Manteca, CA (US);
Ali Mukherjee, Millbrae, CA (US);
Sailaja Pidaparthi, Cupertino, CA (US);
Hossein Salimi-Moosavi, Newbury Park, CA (US);
Yining Shi, Freemont, CA (US);
Sharat Singh, Rancho Santa Fe, CA (US);
Monogram Biosciences, Inc., South San Francisco, CA (US);
Abstract
The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.